Surgical matrices revenue is flat while procedure volumes level out
With elective procedures in the United States mostly back at pre-pandemic levels, the US Surgical Matrices Market returned to what had been normal growth according to SmartTRAK Financial Dashboard. Becton Dickinson* (BD) grew to a 26.9% share, while AbbVie* slipped to second place.Among the many topics covered in detail in our comprehensive Q222 US Surgical Matrices Market Recap* are:
The first half of 2022 has delivered both positive and negative developments for the Computer-Assisted Surgery industry. Supply chain issues and surges of COVID-19 infections have continued to have significant impacts on revenues. At the same time, enabling tech product launches proceed at a rapid pace, with some robotic procedures accelerating. The following is a sample of recent CAS news and developments from around the world, compiled by the expert analysts at SmartTRAK.
We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry. If you'd like to receive these expert insights daily, Contact Us to learn more.
New Products:
SmartTRAK looks at trends in the Diagnostic Aids market for 2022 with an eye on hard-to-heal wounds, regulatory and reimbursement checkpoints and investment deals and financing.
SmartTRAK sees continued growth in the Diagnostic Aids market driven by the following factors:In 2007, the World Union of Wound Healing Societies (WUWHS) published a consensus document on the Principles of Best Practice in Diagnostics and Wounds. The authors identified the need for new diagnostic tests to help identify why some wounds do not respond to advanced therapies. The document further suggested that the ideal diagnostic tool can detect and quantify biomarkers that impact wound healing, such as molecules, biofilms, oxygen content and temperature changes. SmartTRAK looks at trends in the Diagnostic Aids market in 2022 with a focus on ...
To download and read the complete article "Wound Care Diagnostic Aids: Trends to Watch in 2022 and Beyond" just click the button below. 
Georg Schauer, PhD, President of Acandis Inc., discusses the Company, its novel devices and targeting the US market for neurointervention in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) 19th annual meeting held in Toronto, Canada July 25-26, 2022
To find out more about how Acandis plans to differentiate itself and compete in the US market, click on the following video recorded live at SNIS 2022. (11:30 min). A link to download the complete transcript of the interview is also provided below.
Q122 proved to be a mixed-bag of ups and downs with supply chain issues and Covid surges having varying impacts on market leaders’ performance amidst a strong wave of enabling tech product launches.
The Q122 WW CAS Ortho Market was down according to SmartTRAK Financial Dashboard. Stryker* remained the market leader, followed by Zimmer Biomet* and Smith & Nephew*. For detailed Q122 revenues and shares by company in the US, EU and ROW, see the SmartTRAK CAS Ortho Financial Dashboard.
Among the many topics covered in detail in our comprehensive Q122 CAS Ortho Market Recap* are:
Mr J. David Owens, President & CEO of BiologicsMD, and Chief Scientific Officer, Dr. Robyn Goforth, discuss the Company’s highly-targeted therapies, a series of recombinant fusion proteins designed to treat hair loss and severe bone disorders, in an interview with SmartTRAK.
In an interview with SmartTRAK, BiologicsMD President & CEO J. David Owens and CSO Dr. Robyn Goforth discuss BiologicsMD’s innovative highly-targeted treatments for severe bone disorders and hair loss diseases.
To find out more about this early-stage company, the science behind highly-targeted therapies, and two of its lead compounds, click on the following video to listen to the full interview (29:10 min). A link to download a complete transcript of the interview is also provided below.
Q122’s year-over-year growth in the WW Spine market shows normalized, nominal growth for this quarter, which should continue to improve over the course of the remaining year.
The US Spine Hardware market saw double-digit growth versus Q121, showing solid recovery gains from the same period prior year, which seemed to be riddled with ongoing volatility. Segment over segment within the spine market, we’re back to seeing growth in the areas that had been predicable growth segments prior to COVID-19. Although healthcare as a whole continues to rebuild, and staffing remains a challenge, many regions didn’t experience as negative an impact on the Spine market for Q122 as was predicted by many.
Among the many topics covered in detail in our comprehensive Q122 Spine Market Recap* are:
Adam Hattan, VP of Marketing for Route 92 Medical, discusses the Company, its novel system for mechanical thrombectomy and competing in the market for stroke interventions in an interview with SmartTRAK at SNIS 2022.
Amid a growing number of me-too devices, one company that is differentiating itself in the market for stroke thrombectomy is Route 92 Medical (R92). Adam Hattan, R92’s vice president of marketing, discusses R92’s novel system for mechanical thrombectomy and competing in the market for stroke interventions in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) 19th Annual Meeting held in Toronto, Canada July 25-29, 2022.
To find out more about R92, its Monopoint operating platform and the Company’s strategies for growth, click on the following video recorded live at SNIS 2022. (10:13 min). A link to download a transcript of the interview is also provided below.
Although revenues still show signs of COVID-19 impact, robotic procedures and implant pull-through accelerate, and companies continue roll out new spine enabling technology and strategize how to maximize the remainder of 2022.
The Q122 WW CAS Spine Market was up year-over-year according to SmartTRAK Financial Dashboard. Medtronic* (MDT) remained the market leader with 59.5% share, followed by Globus* (GMED) and other enabling tech competitors, including Stryker* (SYK) and Brainlab*.
Among the many topics covered in detail in our comprehensive Q122 CAS Spine Market Recap* are:
Could biosensors and smart dressings be the final frontier in wound diagnostics? SmartTRAK explores the current progress of this market and how it could develop.
It has been 15 years since the World Union of Wound Healing Societies’ Initiative published a consensus document entitled “Diagnostics and Wounds.” Since then, the clinical practice around assessing and diagnosing wounds has not evolved at the same rate as that of treatments. At the same time, the need for improved wound diagnostics has never been greater given burgeoning chronic wound numbers and the continued shift of wound care services to the outpatient setting.
Could the next area of development be that of biosensors and smart dressings? SmartTRAK believes there is increasing evidence that this could be the case. In this article, we explore the developments that are taking place, how the identification of infection biomarkers may be lucrative and ways the market may change in the coming years.
Among the many topics discussed in this article are:
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services.